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With the support of the Biomedical Advanced Research and Development Authority (BARDA) of the US
Department of Health and Human Services, PATH has contributed to the World Health Organization’s
(WHO’s) Global Action Plan for Influenza Vaccines (GAP) by providing technical and clinical assistance
to several developing country vaccine manufacturers (DCVMs). GAP builds regionally based independent
and sustainable influenza vaccine production capacity to mitigate the overall global shortage of influenza
vaccines. The program also ensures adequate influenza vaccine manufacturing capacity in the event of an
influenza pandemic.
Since 2009, PATH has worked closely with two DCVMs in Vietnam: the Institute of Vaccines and
Medical Biologicals (IVAC) and VABIOTECH. Beginning in 2013, PATH also began working with Torlak
Institute in Serbia; Instituto Butantan in Brazil; Serum Institute of India Private Ltd. in India; and
Changchun BCHT Biotechnology Co. (BCHT) in China.
The DCVMs supported under the GAP program all had existing influenza vaccine manufacturing capa-
bility and required technical support from PATH to improve vaccine yield, process efficiency, and product
formulation. PATH has provided customized technical support for the manufacturing process to each
DCVM based on their respective requirements.
Additionally, PATH, working with BARDA and WHO, supported several DCVMs in the clinical develop-
ment of influenza vaccine candidates progressing toward national licensure or WHO prequalification. As
a result of the activities outlined in this review, several companies were able to make excellent progress
in developing state-of-the-art manufacturing processes and completing early phase clinical trials.
Licensure trials are currently ongoing or planned for several DCVMs.
 2016 Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
Since 2009, with the support of the Biomedical Advanced
Research and Development Authority (BARDA) of the US Depart-
ment of Health and Human Services, PATH has contributed to the
World Health Organization’s (WHO’s) Global Action Plan for Influ-
enza Vaccines (GAP) by providing technical and clinical assistance
to several developing country vaccine manufacturers (DCVMs).
Technical assistance included direct support in manufacturing pro-
cess development, including process yield optimization, process
validation, analytical method development and validation, quality
control, and quality management systems (implementing and
strengthening good manufacturing practices (GMP)). Clinical assis-
tance included clinical trial design, implementation, laboratorytesting, and regulatory support. Moreover, PATH country offices
managed technical and clinical development and facilitated daily
regulatory interactions. PATH also facilitated interactions with
the US Centers for Disease Control and Prevention (CDC) for serol-
ogy testing and reagents, the National Institutes for Biological
Standards and Control (NIBSC) for vaccine potency and standards,
and academic institutions in Europe and the United States for
training on analytical methods. PATH also provided DCVMs with
introductions to the relevant WHO personnel and meetings neces-
sary for influenza strain selection.
The DCVMs varied in their capacity to develop new products.
Some companies had vaccines on the market but were only expe-
rienced with legacy processes and had limited in-house develop-
ment capacity. Other companies had the technical skills to
develop new manufacturing processes but needed to improve
quality standards or lacked clinical development expertise. There-
fore, PATH provided customized support, initiated by due diligence
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and existing gaps. Relevant PATH staff or consultants then worked
with each DCVM to develop a tailored technical assistance plan
beginning with a series of on-site visits and as-needed trainings
followed by email and teleconference communications.
Vaccine manufacturers that received assistance for national
product licensure followed pharmacopeias and national guidelines
(when available) in product development and testing, and in clin-
ical trial design and implementation. For WHO pre-qualification,
manufacturers observed WHO and European Medicines Agency
or US Food and Drug Administration (FDA) guidelines, which fre-
quently proved to be more stringent than local guidelines. PATH’s
core functions and experts, including chemistry, manufacturing,
and controls (CMC), clinical, regulatory, and business development,
were involved as part of the provided technical assistance.
This review outlines the most frequent observations found dur-
ing PATH’s CMC, regulatory, and clinical trial support activities, and
briefly outlines the remediation, improvements, and progress
made in the development of regional capacities for influenza vac-
cine production.2. CMC technical assistance
This section discusses the most common challenges experi-
enced by DCVMs developing and producing influenza vaccines.
This section also details how PATH’s technical staff and consultants
provided training, expert advice, and strategies to prevent and
remediate such challenges.
Most manufacturers supported under the GAP program were
developing a conventional egg-based process for seasonal split vac-
cines, and a whole-virion approach for pandemic vaccines (see
Fig. 1). Low-resource country manufacturers frequently use egg-
based influenza vaccines because the technology is already well-
established, and quality eggs are readily available. In the DCVMs
PATH was supporting, however, vaccine yields were often low
because the manufacturers were not using mass balance with sin-
gle radial immunodiffusion (SRID) (or high performance liquid
chromatography (HPLC)) to determine the hemagglutinin (HA)
yields of each step in the process. When instituted, however, the
steps responsible for such large losses in yield became obvious
and remediation efforts could be implemented to improve yield.2.1. Seed development
Seasonal influenza vaccine formulations can vary year-to-year.
Vaccine manufacturers procure the seed viruses from laboratories
that generate reassortants. These viruses combine the surface
immunological antigenic properties of the circulating viruses and
the growth properties of strains that have proven to grow well in
eggs. Frequently, the DCVMs were unaware that differences in
yield can occur between the various reassortants and genetically
engineered viruses. Using the optimal seed virus, however, can
sometimes improve production yields by two- to three-fold. PATH
invited the DCVMs to participate in the yearly WHO technical calls
where seed information is discussed, and provided assistance in
choosing the best seed viruses. The laboratories began using ideal
seed optimization methods, such as serial passaging in eggs with
relatively high concentration of virus that allows the rare better-
growing mutants to outgrow the average-yielders. Additionally,
short incubation periods allow the faster-growing mutants to pre-
vail, and those mutants often result in the highest yields after the
full incubation period. Finally, many RNA viruses tend to cycle in
their yields. Sequential passaging of virus affects the ratio of defec-
tive interfering particles to live virus, so it is necessary to choose
the correct passaging conditions as well as the correct number ofpassages for optimal seed virus. Appropriate understanding of
these concepts led to significant improvements in the yield.
It is important to produce a seed that, when inoculated for the
pass in large scale production, will give the best HA yields. This can
be done by tracking the yields for small-scale passage and replicat-
ing the relevant passage to produce large quantities of working
seed. Once a working seed had been made, however, none of the
DCVMs were doing the additional work required to identify opti-
mal incubation time and dilution for production. Small-scale
time/dilution studies can provide guidance to improve
production-scale yields. Inclusion of these studies also resulted in
significant improvement in viral titer at harvest and overall process
for the various DCVMs.
Finally, it is important (especially for pre-pandemic strains) to
connect with authorities who will confirm the working seed has
not changed with regard to antigenicity or sequence of the poly-
basic region of the HA. Changes in some of the amino acids in
the hemagglutinin are often associated with increased yield versus
changes in antigenicity. Rarely, some seeds can change their anti-
genicity after as few as one or two passages. Change impact can
be assessed using ferret antiserum panels and reference viruses.
Since ferret panels are difficult to produce, it is important for
DCVMs to connect with a WHO reference laboratory to outsource
product testing.2.2. Egg handling and fluid clarification
Egg contamination is a major concern in vaccine production.
PATH educated DCVMs on the best way to handle eggs in order
to protect the cuticle (the outer coating on the shell that makes
eggs less porous and reduces contamination). PATH also impressed
upon manufacturers the importance of routine monitoring, as
many were unaware that water used for incubator humidification
can be a prime source of bioburden contamination. PATH also
taught manufacturers that egg fumigation is much more effective
in reducing egg-shell contamination because it kills bacteria before
they have a chance to enter the egg at day 0 instead of day 11.
Finally, PATH encouraged manufacturers to discard grossly con-
taminated eggs rather than wash them and risk losing the protec-
tive cuticle.
Some of the facilities that received technical assistance had
access to modern automatic or semi-automatic egg inoculation
and harvesting equipment. Typically, DCVM were aware of and
routinely implemented methods to reduce egg contamination by
frequently changing or cleaning the inoculation needles and visu-
ally inspecting eggs after decapping before harvesting. Fluid clari-
fication, however, was often performed using filtration through
membranes that were too tight, resulting in excessive loss of virus
yields. The main purpose of the clarification step is to remove large
debris and red cells; filters with a pore size small enough to
remove bacteria are likely to remove virus as well, depending on
the quality of each particular batch of allantoic fluid. PATH recom-
mended use of larger pore filters and, where possible, a filter cas-
cade from large to small pores or low speed centrifugation,
which greatly improved yields. Using excessive speed was a com-
mon error for the low speed centrifugation process, particularly as
influenza virus tends to clump loosely and relatively low speeds
can pellet some of the virus. However, the centrifugation speed
and fluid flow rate can be adjusted to apply only the minimum g
force needed to pellet red cells without pelleting the virus.2.3. Purification, inactivation, and filtration
The typical downstream process for both split and whole virion
vaccines includes a step to purify the virus from the infected
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Fig. 1. Diagram of the manufacturing process and development activities for egg-based vaccine manufacturing.
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and chemically inactivated.
I. Purification: All facilities were using standard zonal cen-
trifugation to purify the virus. PATH experts recommended
studies that determined which fractions needed to be
included in the retained virus band in order to reduce con-
taminants and optimize viral recovery.
II. Viral inactivation: Some facilities were using more formalin
or Beta-propiolactone (BPL) than was needed for viral inac-
tivation, resulting in unnecessary losses of HA. PATH experts
helped identify the correct amount of formalin or BPL and
recommended use of a standard two vessel procedure dur-
ing inactivation to ensure complete viral inactivation.
Other occasional problems included:
 Inadequate temperature control.
 Inadequate amounts of detergent (Triton X-100) following
dialysis (of split vaccines), which led to excess aggregation of
the HA, thus causing losses both in-process and during stability
monitoring. Inadequate membrane cleaning, either before or after zonal
centrifugation, which led to the addition of bioburden in subse-
quent lots.
 Increased pressure during the dialysis and final filtration steps,
for both whole and split vaccines.
 Inadequate membrane surface area.
III. Filtration: Introducing controlled cross filtration parameters
such as Liters/Meter/Hour and Trans-Membrane-Pressure
improved processes and resulted in higher recovery and
better filtration efficiency and contaminant removal. Despite
this improvement, the filtration steps were sometimes per-
formed with vaccine at too high a concentration so that
aggregation and subsequent losses were more likely. This
could easily be corrected by defining appropriate ranges
for the tangential flow filtration steps to reduce losses and
ensure lot-to-lot consistency.
2.4. Formulation
Blending monovalent bulks to formulate the final product has
been a major focus. Inactivated trivalent seasonal influenza vacci-
nes are blended so each strain is present in the final product in an
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impacts the final formulation because loss of potency over time
must be factored in the initial product formulation. The overage
required can be experimentally determined and must account for
product loss during process and storage. One important factor is
that, once influenza virus is split with detergent, disulfide bonds
start to form and cause aggregation of HA. The cross-linked pro-
teins will not diffuse properly in the SRID test and will result in a
lower amount of measured immunoreactive HA [1]. This cross-
linking tends to stabilize after about a month of monovalent con-
centrate storage. Understanding the concentrate stability curve is
important in order to adjust formulation targets. Trivalent bulk
stability data is also important and for a new strain, stability
should be anticipated from data from previous related strains.
Most of these elements are unique to influenza vaccines. Several
DCVMs developing influenza vaccine for the first time did not have
the experience to efficiently anticipate and resolve these chal-
lenges. External support was necessary to ensure the final product
would remain potent during long-term stability testing and clinical
trials.
Another important consideration was the use of adjuvants.
PATH recommended against using adjuvants in the seasonal vac-
cine formulation based on limited efficacy of aluminum-based
adjuvants, and the complexity and risks involved in developing
more potent adjuvants (such as oil-in-water squalene-based ones).
Split pandemic vaccines have been shown to be poorly immuno-
genic for influenza A/H5N1 and require either very high doses
(90 lg hemagglutinin per dose) or potent proprietary adjuvants
to be effective. Existing alum-adjuvanted whole-virion A/H5N1
vaccines have shown acceptable safety profiles and good immuno-
genicity in clinical trials [2,3]. Based on these data, PATH recom-
mended DCVMs pursue development of an alum-adjuvanted
whole-virion A/H5N1 vaccine.
2.5. Manufacturing process yields
The typical influenza vaccine yield is usually estimated to be
about one 45 lg trivalent dose per egg harvested. This standard
does not take into account formulation and filling losses, though
it does include an average yield of all three strains in a trivalent
vaccine (when possible). By implementing the manufacturing
improvements described above in Sections 2.1–2.3, manufacturers
were able to improve the overall yield. For example, in one case
yield increased from 0.25 dose/egg to 1.30 dose/egg. Another
manufacturer increased from about 0.13 dose/egg to about
1.00 dose/egg.
2.6. Process validation
Once a manufacturing process is deemed satisfactory, a devel-
oper should determine acceptable operating ranges to ensure pro-
duction batch consistency (known as process validation (PV)). This
needs to be completed before the vaccine enters late-stage clinical
development, to guarantee the material used in development will
be representative of the commercial product.
Occasionally, there were an inadequate number of developmen-
tal runs prior to PV. These runs are essential to determine critical
quality attributes and process parameters and should be well
planned and documented. Manufacturers should consider the bio-
logical variability of influenza virus strains and eggs to determine
ranges of the study parameters to understand the inherent vari-
ability of the process.
At times, assay validation, cleaning validation, hold time deter-
mination, and mixing validation were not completed before PV.
Inexperienced laboratories had a tendency to set acceptance
criteria and specifications too tightly, increasing the likelihood offailure during PV or routine production. PATH helped these facili-
ties draft PV plans before initiating PV activities.
2.7. Analytical development
Analytical testing development or quality control laboratories
had variable levels of resources available which affected in-
process and product release testing. Some laboratories were lim-
ited by types of equipment and others by limited experience in
appropriate application of methodologies.
As an example, in place of the HPLC-based method typically
used in high resource pharmaceutical laboratories, PATH intro-
duced for one manufacturer a colorimetric assay to measure vac-
cine Triton levels.
The SRID potency assay, also used during in-process testing to
determine yield at various steps, presented problems for laborato-
ries that did not dilute the samples. For samples with low HA, such
as allantoic fluid, a full dilution SRID was not possible so PATH rec-
ommended a modified single point SRID. HA measurement at har-
vest can be confounded by the presence of HA not bound to virus
particles, yet an approximation of hemagglutinin concentration
at harvest was instrumental to study and optimize downstream
process recovery.
HPLC can be a simple and efficient substitute for SRID when
measuring total HA for in-process monitoring [4]. While HPLC only
indicates total HA mass and cannot be used to measure stability, it
can be a useful tool to measure and optimize recovery at specific
process steps. For laboratories that had HPLC equipment, PATH
provided the required support to develop the assay and sample
preparation methods.3. Quality management systems and common challenges
Good manufacturing practices (GMP), quality, production, facil-
ities and equipment, laboratory controls, materials, and packaging
and labeling sit under the broad umbrella of a quality management
system (QMS). All manufacturers need appropriate QMS in place to
adequately support these various systems and ensure product
safety and efficacy. PATH QMS experts worked with several DCVMs
to assess existing quality systems, mitigate gaps, and strengthen
overall quality systems. Most efforts were focused in three areas:
deviation identification, investigation, and risk management;
method validation and documentation; and data integrity
management.
3.1. Deviation identification, investigation, and risk management
New standard operating procedures (SOPs) had to be developed
to delineate the deviation identification, investigation, and correc-
tive processes. PATH experts worked with Quality Assurance (QA)
staff to implement the SOPs under GMP. One of the primary goals
was to foster a culture change in which deviations could be
accepted as normal instead of as an admittance of failure. SOP
implementation and appropriate deviation management led to
new reporting systems that are routinely presented to the upper
management teams.
3.2. Quality control: Method validation
Method validation is the process used to confirm that an analyt-
ical test is suitable for its intended use. Results from method vali-
dation can be used to judge the quality, reliability, and consistency
of analytical results; it is an integral part of any good analytical
practice [5]. Some DCVMs did not have the time and resources to
develop, optimize, and validate methods for critical assays. In some
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method validation, the process and parameters by which to do so
were not well understood.
Much of PATH’s work emphasized method optimization, valida-
tion, and implementation. Again, PATH worked with DCVM analyt-
ical teams and QA staff to develop SOPs that guide method
development, documentation, and validation. To provide on the
job training, PATH quality and analytical method experts then
worked with testing teams to develop new methods and work
through method validation of several new and existing methods
using the newly developed guidance SOPs. It is important to note
that while the validation SOP was derived from FDA guidelines
[5], the manufacturers followed national pharmacopeias for indi-
vidual method validation or verification. Establishing formal proce-
dures allowed for a more seamless transition into the overall QMS,
because deviations could be identified, tracked, and managed as
needed.
3.3. Quality control: Documentation and data integrity management
Perhaps the area that has required the most focus is
documentation. From process or method development to final
manufacturing process and conduct of process and method
validation, in-process and release testing, all steps have to be
meticulously recorded. Most importantly, the records have to be
traceable and data integrity has to be proven and maintained. This
applies to everything from appropriate documentation and storage
of raw data, to notebooks and test records. PATH QMS experts
worked with DCVM staff to develop appropriate documentation
and systems that allowed manufacturing and process oversight
by the Quality Assurance staff.4. Common challenges in clinical trial implementation
Even under the best of circumstances and in countries with
clear laws and policies on vaccine research, scientific, operational,
and regulatory challenges inevitably arise when conducting clini-
cal trials. This section highlights some of the challenges associated
with planning and executing influenza vaccine candidate trials in
low- to middle-resource countries that import most of their vacci-
nes, including interpretations of the regulatory framework; the
ethical review process; lack of effective community engagement;
and laboratory issues.
4.1. Regulatory framework
The regulatory framework refers to the regulations and guid-
ance documents that identify proper practices for drug or biologic
manufacturing, testing, and product approval in a country. A
proper regulatory framework provides a clear path for licensing
approval.
Many countries have underdeveloped regulatory frameworks
for clinical trial conduct, particularly on how to advance vaccines
through the process [6]. In one country, where there are no existing
regulations for influenza vaccine candidates, PATH and an experi-
enced contract research organization provided technical assistance
that led to implementation of the country’s first-ever vaccine trial
in healthy adults with a seasonal influenza vaccine candidate. This
required PATH to provide training to governmental agencies on
both vaccine clinical trials and research in healthy adults.
In countries where regulators are inexperienced, the default
impulse is—understandably—one of excessive caution and unwill-
ingness to deviate from familiar country guidelines. For instance,
when a Phase 1 seasonal influenza study shows a favorable safety
and immunogenicity profile and the dose selection has alreadybeen well established (as in the case of seasonal influenza vacci-
nes), it can be reasonable to proceed directly to a Phase 3 licensure
trial. If the guidelines lack this mechanism explicitly, however, it
can be difficult to advance the approach in countries with inexpe-
rienced regulators. As a result, clinical trial planning for seasonal
influenza vaccine may include an unnecessary Phase 2 component,
which requires regulatory authority evaluation before proceeding
to the Phase 3 licensure trial. This additional phase in the clinical
development of a widely accepted vaccine adds complexity, leads
to licensure delays, and further constrains resources that may be
better used elsewhere.4.2. Ethical review process
The independent ethical review process is a critical function
that ensures the protection of research subjects in clinical trials
[7]. Generally, review is satisfied by a committee composed of sci-
entists, non-scientists, and at least one person who is not affiliated
with the principal investigator’s institution. Though single research
proposals are frequently reviewed by multiple ethics committees,
this is typically limited to multicenter trials. Sometimes, however,
even though only one institution is interacting with research par-
ticipants the ethics committees of other organizations providing
financial support, technical assistance, etc. require review of the
trial dossier. Several DCVM influenza vaccine trials, even though
conducted at a single site in one country, were subject to three
or four ethics committee reviews. This creates an undue burden
on the research team and results in only marginal improvement,
if any, of the research plan. Moreover, in PATH’s case, the need
for multiple translations of the documents further complicated
the review. Some of the burden can be mitigated by use of an
authorization agreement, a method that allows one institutional
review board (IRB) to rely on the review of another, but this is only
a partial solution [7]. Significant effort is needed to harmonize the
multiple reviews, ensure committees are aware of the changes
required by one another, and finally produce one version of the
protocol and consent that achieves approval from all committees
in the necessary languages. Additional challenges arise when ethics
committees have opposing views and the research team has to
develop a compromise acceptable to all committees.4.3. Laboratory challenges
In early phase vaccine research, clinical laboratory screening
can be an important factor in determining eligibility and detecting
any abnormalities that may be elicited by the vaccine. Laboratory
results help establish that a person is in good health and able to
participate in the vaccine research. In addition, clinical laboratory
tests conducted during the trial can establish adverse events or
better explain the clinical picture of a participant who may have
physical signs of illness. Endpoint laboratory testing can help
determine whether or not a vaccine candidate should progress to
later phase testing.
Inexperienced laboratories lacking in resources posed a chal-
lenge for influenza vaccine trials with DCVMs. In general, a lack
of resources creates a lack of items that would be considered stan-
dard practice for clinical trials (such as temperature monitoring
equipment). Laboratories may also lack standard certifications of
properly functioning equipment, such as centrifuges—critical to
preparing specimens for aliquot and storage.
Frequently PATH helped build laboratory capacity, train staff,
and facilitate the receipt of appropriate control reagents for the
assays. For example, some laboratories were trained to perform
hemagglutination inhibition and microneutralization testing to
support clinical development of both seasonal and pandemic
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4.4. Lack of effective community engagement/recruitment
Community engagement is increasingly regarded as an impor-
tant ethical practice in clinical research [8]. Though it is a key
requirement for some areas of study, it is not widely practiced
around the world due to the additional time and resources
required before research begins.
At the most basic level, community engagement informs the
community about planned research, the disease under study, and
the aim of the study. At the highest level, community engagement
includes community representatives in the research design, imple-
mentation, and dissemination of results.
The DCVMs that initiated influenza vaccine research experi-
enced confusion between community engagement and recruit-
ment. Recruitment is a process of inviting potential trial
participants to join a study. Recruitment activities must
be reviewed and approved by an IRB/ethics committee before the
activities can begin, because recruitment is the start of the
informed consent process. If community engagement is to be fully
effective, it should begin before the ethics committee approves the
research, so community attitudes and feedback can help guide
materials developed for trial participants. Community input can
also help frame issues critical to recruitment and retention, such
as how participants should be contacted by the study team and
how the study team can make participants comfortable. Good
community engagement should inform the community about the
health issue being studied and the upcoming vaccine trial (without
recruiting), and ask about community concerns.
A lack of community engagement can create an information gap
that negative attitudes and rumors might fill—which sometimes
make their way to the media, fostering concern and distrust over
clinical trial operations. Rumors surrounding one influenza trial
claimed, in the absence of any evidence, that the vaccine was
harmful and volunteers would not be compensated in the case of
adverse effects. Such rumors made volunteer enrollment a chal-
lenge, and eventually required study staff to conduct home visits
and host community meetings to build trust and reverse the dam-
age rumors had done. Engaging the community before the trial
began and providing education on the influenza virus, the vaccine
trial, and the importance of the research would have better pre-
pared the community and potentially prevented rumors from
starting.
Similarly, some GAP countries opposed recruitment by
advertisement. Subsequently, recruitment was limited to
word-of-mouth and, in some countries, physician referral. This
further hampered trial recruitment, since word-of-mouth can lead
to misinformation about the research or the vaccine.
5. Conclusion
Since 2009, PATH has worked with several DCVMs on various
aspects of manufacturing, testing, quality, and clinical develop-
ment. Each DCVM has unique strengths and areas of expertise,
which have allowed successful partnerships with international
organizations such as BARDA, WHO, and PATH to develop and
advance new products.
Under the GAP, and with direct support from PATH, DCVMs
have made considerable progress in influenza vaccine
development capacity. In particular, DCVMs have achievedoptimized manufacturing conditions, increased yield, and vaccine
capacity. DCVMs that initially lacked internal clinical teams, did
assign staff to learn the clinical development process and are
now working to develop clinical teams in-house. Certainly, DCVMs
now have more capacity to implement clinical trials in compliance
with international standards. And because QMS has been strength-
ened overall, the DCVMs are poised to produce high quality, low
cost, efficacious vaccines to reduce the global burden of influenza.
Already several manufacturers have advanced both seasonal and
pandemic vaccine candidates that are in early clinical develop-
ment, while others have candidates that are on the pathway to
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